© ACCESS Newswire
11.12.2024
EVT
LISTED
XETR
Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk
News Preview
Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseasesLAB eN² is also expanding, adding Boston Children's Hospital, Boston University, Johns Hopkins University, Joslin...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2024
MOB
LISTED
STO
Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU
News Preview
STOCKHOLM, Dec. 10, 2024 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announces that MOB-015 (topical terbinafine) did not meet the primary endpoint in the phase 3 study using 8 weeks of daily dosing followed by weekly maintenance dosing. The company's focus going forward will be on the effective daily dosing regimen approved in 13 EU countries....
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2024
ZEAL
LISTED
CPH
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
News Preview
Press Release – No. 12 / 2024...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
10.12.2024
HELP
LISTED
NASDAQ
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
News Preview
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the presentation of two posters at the American College of Neuropsychopharmacology (“ACNP...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
10.12.2024
LEGN
LISTED
NASDAQ
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma
News Preview
SOMERSET, N.J., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today new results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) provided significantly higher rates of minimal residual diseas...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.12.2024
AUTL
LISTED
NASDAQ
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
News Preview
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2024
RXRX
LISTED
NASDAQ
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
News Preview
SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2024
EAPI
LISTED
EURONEXT
EUROAPI moves into a new chapter with new Governance and Leadership
News Preview
Paris – December 9, 2024 – With FOCUS-27 strategic plan foundations established and its financing secured, EUROAPI moves into a new chapter. The company’s Board of Directors has accepted today the resignation of Viviane Monges as Director and Chair of the Board and Ludwig de Mot as Chief Executive Officer. Consequently, upon the recommendation of t...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2024
GMAB
LISTED
CPH
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
News Preview
Media ReleaseCOPENHAGEN, Denmark; December 9, 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2024
KDEV
LISTED
STO
Karolinska Development's portfolio company Modus Therapeutics initiates a phase 2 study with sevuparin for treatment of chronic kidney disease with anemia
News Preview
STOCKHOLM, SWEDEN – December 9, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has dosed the first patient in a phase 2 clinical study of the drug candidate sevuparin, evaluated as a treatment for chronic kidney disease with anemia. The study is being conducted at Centro Rice...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2024
SECT_B
LISTED
STO
Norwegian healthcare region expands enterprise imaging contract with Sectra--digitizes pathology diagnostics to improve cancer care
News Preview
LINKÖPING, Sweden, Dec. 9, 2024 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) announces that the Norwegian healthcare region Helse Nord RHF will expand its usage of Sectra's enterprise imaging solution to include digital pathology. The digital workflow will make it easier for pathologists to revie...
Themefolio
Profiler
Peergroup
© PR Newswire
09.12.2024
IMMNOV
LISTED
STO
Immunovia announces positive outcome and strong accuracy in the clinical validation of its next-generation test for pancreatic cancer
News Preview
LUND, Sweden, Dec. 9, 2024 /PRNewswire/ -- Immunovia (STO: IMMNOV), the pancreatic cancer diagnostics company, today announces the successful completion of the CLARITI study, (Clinical Validation of Next-Generation Test for Early-Stage Pancreatic Cancer) to detect early-stage pancreatic ductal adenocarcinoma (PDAC).
In the study of over 1,000 pa...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© EQS Newswire
09.12.2024
FYB
LISTED
XETR
MS Pharma wird Kommerzialisierungspartner für FYB202 / Ustekinumab in der MENA-Region
News Preview
Pressemitteilung // 09. Dezember 2024
MS Pharma wird Kommerzialisierungspartner für FYB202 / Ustekinumab in der MENA-Region
Planegg-Martinsried, Amman, Jordanien – Die Formycon AG (FWB: FYB, Prime Standard, "Formycon" oder "Gesellschaft") und MS Pharma geben gemeinsam bekannt, dass sie eine Lizenz- und Liefervereinbarung für die Vermarktung von......
Themefolio
Profiler
Peergroup
© EQS Newswire
09.12.2024
FYB
LISTED
XETR
MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region
News Preview
Presse Release // December 09, 2024
MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region
Planegg-Martinsried, Germany / Amman, Jodan – Formycon AG (FSE: FYB, Prime Standard) and MS Pharma jointly announce that they have entered into a licensing and supply agreement for the commercialization of FYB202, F......
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2024
BLUE
LISTED
NASDAQ
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
News Preview
bluebird bio, Inc. (Nasdaq: BLUE) today announced new and updated data from LYFGENIA™ (lovotobegligene autotemcel, or lovo-cel) gene therapy for patients with sickle cell disease who have a history of vaso-occlusive events (VOEs). The data will be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in an oral p...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2024
GMAB
LISTED
CPH
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
News Preview
Media ReleaseCOPENHAGEN, Denmark; December 8, 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.12.2024
GMAB
LISTED
CPH
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
News Preview
Media ReleaseCOPENHAGEN, Denmark; December 7, 2024...
Themefolio
Profiler
Peergroup
© BusinessWire
07.12.2024
BLUE
LISTED
NASDAQ
Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
News Preview
bluebird bio, Inc. (Nasdaq: BLUE) today announced updated data from patients with beta-thalassemia who require regular blood transfusions treated with betibeglogene autotemcel (beti-cel, approved commercially as ZYNTEGLO™) in clinical studies. The data was presented today at the 66th American Society of Hematology (ASH) Annual Meeting and Expositi...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.12.2024
GLPG
LISTED
EURONEXT
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
News Preview
Mechelen, Belgium; December 7, 2024, 18:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced additional data from the ongoing Phase 1/2 ATALANTA-1 study of its CD19 CAR T-cell therapy, GLPG5101. The results, featured in an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, demonstrate an...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.12.2024
IBAB
LISTED
EURONEXT
NOTICE OF A GENERAL MEETING OF IBA SA
News Preview
NOTICE OF A GENERAL MEETING OF IBA SA...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.12.2024
IBAB
LISTED
EURONEXT
IBA - Information réglementée
News Preview
structure actionnariat 20241206.pdf structure actionnariat 20241206.pdfIBA SA – Information réglementée...
Themefolio
Profiler
Peergroup
© EQS Newswire
06.12.2024
SRT3
LISTED
XETR
Michael Grosse to succeed Joachim Kreuzburg as Chief Executive Officer of Sartorius AG
News Preview
Göttingen, December 6, 2024
Michael Grosse to succeed Joachim Kreuzburg as Chief Executive Officer of Sartorius AG
Grosse to take over as Group CEO on July 1, 2025
At its meeting today, the Supervisory Board of Sartorius AG appointed Dr. Michael Grosse Chief Executive Officer of Sartorius. He will take over this position on July 1, 2025, from D......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.12.2024
SRT3
LISTED
XETR
Michael Grosse folgt auf Joachim Kreuzburg als Vorstandsvorsitzender der Sartorius AG
News Preview
Göttingen, 6. Dezember 2024
Michael Grosse folgt auf Joachim Kreuzburg als Vorstandsvorsitzender der Sartorius AG
Grosse wird Konzernleitung zum 1. Juli 2025 übernehmen
Der Aufsichtsrat der Sartorius AG hat in seiner heutigen Sitzung Dr. Michael Grosse zum künftigen Vorstandsvorsitzenden des Konzerns ernannt. Er wird diese Aufgabe am 1. Juli ......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.12.2024
SRT3
LISTED
XETR
Michael Grosse wird Vorstandsvorsitzender der Sartorius AG
News Preview
Veröffentlichung einer Insiderinformation gemäß Artikel 17 MAR
Michael Grosse wird Vorstandsvorsitzender der Sartorius AG
Der Aufsichtsrat der Sartorius AG hat in seiner heutigen Sitzung die Bestellung von Dr. Michael Grosse zum Mitglied des Vorstands und Vorstandsvorsitzenden (CEO) der Gesellschaft mit Wirkung zum 1. Juli 2025 und einer Laufzeit v......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.12.2024
SRT3
LISTED
XETR
Michael Grosse to become Chief Executive Officer of Sartorius AG
News Preview
Disclosure of inside information according to Article 17 MAR
Michael Grosse to become Chief Executive Officer of Sartorius AG
At its meeting today, the Supervisory Board of Sartorius AG resolved to appoint Dr. Michael Grosse as member of the Executive Board and Chief Executive Officer of the company with effect from July 1, 2025, for a term of th......
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2024
HNSA
LISTED
STO
Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease
News Preview
Data from the trial is expected to be shared in 2025
LUND, Sweden, Dec. 5, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) today announced it has completed the enrolment of patients in the GOOD-IDES-02 trial, a global pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease. Anti-GBM is a rare, severe a...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2024
HNSA
LISTED
STO
Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease
News Preview
Data from the trial is expected to be shared in 2025
LUND, Sweden, Dec. 5, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) today announced it has completed the enrolment of patients in the GOOD-IDES-02 trial, a global pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease. Anti-GBM is a rare, severe a...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.12.2024
COLO B
LISTED
CPH
Coloplast A/S - Decisions at the Annual General Meeting 2024
News Preview
Today, 5 December 2024, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted:...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2024
LIVN
LISTED
NASDAQ
LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its participation in the American Epilepsy Society (AES) 2024 Annual Meeting, taking place December 6-10 in Los Angeles. The Company’s therapies and technologies for drug-resistant epilepsy treatment will be featured in numerous scientific posters to support...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2024
ICLR
LISTED
NASDAQ
ICON Survey Highlights Sustained Investment in AI and Digital R&D Innovation, Tempered by Siloed Adoption
News Preview
ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced results from a recent global survey of 101 biotech and pharma professionals across Europe and North America to understand the trajectory of AI and digital innovation adoption within clinical research.
Respondents revealed t...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2024
DFTX
LISTED
NASDAQ
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD), has been granted an Innovation Passport for the potential treatme...
Themefolio
Profiler
Peergroup
© EQS Newswire
05.12.2024
FYB
LISTED
XETR
Formycon steigt in den SDAX der Deutschen Börse auf
News Preview
Pressemitteilung // 05. Dezember 2024
Formycon steigt in den SDAX der Deutschen Börse auf
Formycon-Aktie gehört künftig zur DAX-Indexfamilie und zu den 70 größten deutschen Unternehmen unterhalb des MDAX
Attraktivität der Aktie steigt nach kürzlich erfolgtem Uplisting in den Prime Standard
Aufnahme in den Auswahlindex ab 23. Dezember 2024 wirks......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.12.2024
FYB
LISTED
XETR
Formycon joins the SDAX of the German Stock Exchange
News Preview
Press Release // December 5, 2024
Formycon joins the SDAX of the German Stock Exchange
Formycon shares will be part of the DAX index family, ranking among the 70 largest German companies below the MDAX
Enhanced share attractiveness following recent uplisting to the Prime Standard
Formycon shares to be included in the index effective as of Decem......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.12.2024
EUZ
LISTED
XETR
Eckert & Ziegler und Ariceum Therapeutics unterzeichnen globalen Liefervertrag für die Entwicklung von Radiotherapeutika der nächsten Generation im Bereich der präzisen Krebsbehandlung
News Preview
Berlin, 5. Dezember 2024. Eckert & Ziegler, einer der weltweit größten Anbieter von Isotopen für medizinische, wissenschaftliche und industrielle Zwecke, und Ariceum Therapeutics (Ariceum), ein privates Biotech-Unternehmen, das radiopharmazeutische Produkte für die Diagnose und Therapie bestimmter schwer zu behandelnder Krebsarten entwickelt, g......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.12.2024
EUZ
LISTED
XETR
Eckert & Ziegler and Ariceum Therapeutics Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments
News Preview
Berlin, 5 December 2024. Eckert & Ziegler, one of the world’s largest providers of isotopes for medical, scientific and industrial use, and Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced the signing of a global su......
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2024
BIOA B
LISTED
STO
First patient dosed in EXIST Phase 2a study in Parkinson's disease
News Preview
STOCKHOLM , Dec. 5, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient has been dosed with exidavnemab in the EXIST Phase 2a study, in Parkinson's disease patients. Exidavnemab is a monoclonal antibody designed to target aggregated forms of the protein α-synuclein, believed to play a role i...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2024
BIOA B
LISTED
STO
First patient dosed in EXIST Phase 2a study in Parkinson's disease
News Preview
STOCKHOLM , Dec. 5, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient has been dosed with exidavnemab in the EXIST Phase 2a study, in Parkinson's disease patients. Exidavnemab is a monoclonal antibody designed to target aggregated forms of the protein α-synuclein, believed to play a role i...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2024
BIOA B
LISTED
STO
Leqembi® approved in Mexico
News Preview
STOCKHOLM, Dec. 5, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved Leqembi (lecanemab) for the treatment of early Alzheimer's disease (AD)1.
Leqembi selectively binds to soluble amyloid-beta...
Themefolio
Profiler
Peergroup
© PR Newswire
05.12.2024
BIOA B
LISTED
STO
Leqembi® approved in Mexico
News Preview
STOCKHOLM, Dec. 4, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved Leqembi (lecanemab) for the treatment of early Alzheimer's disease (AD)1.
Leqembi selectively binds to soluble amyloid-beta...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2024
BLUE
LISTED
NASDAQ
bluebird bio Announces 1-for-20 Reverse Stock Split
News Preview
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it will proceed with a 1-for-20 reverse stock split (“Reverse Stock Split”) of the Company’s common stock following approval by both its Board of Directors and BLUE stockholders at its reconvened annual meeting held on December 4, 2024. As previously announced...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2024
OSE
LISTED
EURONEXT
OSE Immunotherapeutics : Informations Relatives au Nombre Total de Droits de Vote et d’Actions Composant le Capital
News Preview
Informations Relatives au Nombre Total de Droits de Vote et d’Actions Composant le Capital...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2024
BLUE
LISTED
NASDAQ
bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model
News Preview
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio”) today announced it has reached an agreement with the Center for Medicare and Medicaid Innovation to offer an outcomes-based agreement for LYFGENIA gene therapy under the Cell and Gene Therapy (CGT) Access Model. LYFGENIA is a one-time gene therapy approved for the treatment of patients 12 years of...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2024
EHAB
LISTED
NYSE
Delaware Court of Chancery Awards Damages and Other Relief to Encompass Health and Enhabit for Misconduct by April Anthony, Other Former Officers, and Private Equity Firms Vistria Group and Nautic Partners
News Preview
On Monday, Encompass Health and Enhabit won their lawsuit in the Delaware Court of Chancery related to breaches of fiduciary duty by April Anthony, Luke James, and Chris Walker while they served as the senior officers at Encompass Health’s former home health and hospice division, which is now Enhabit. The Court awarded judgment against private equ...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2024
AMRX
LISTED
NASDAQ
Amneal to Participate at Upcoming Investor Conferences
News Preview
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical company, announced today that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in two upcoming investor conferences.
36th Annual Piper Sandler Annual Healthcare Conference
December...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2024
HELP
LISTED
NASDAQ
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024
News Preview
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, and Amir Inamdar, MBBS, DNB (...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.12.2024
COLO B
LISTED
CPH
Coloplast divests core Skin Care product portfolio
News Preview
The divestment is part of a strategic initiative to simplify business operations and improve profitability in the Advanced Wound Care business area....
Themefolio
Profiler
Peergroup
© EQS Newswire
04.12.2024
1SXP
LISTED
XETR
SCHOTT Pharma unveils innovative nest design for ready-to-use cartridges
News Preview
Next-level efficiency and sustainability: SCHOTT Pharma unveils innovative nest design for ready-to-use cartridges
New diamond-shaped nest design for ready-to-use (RTU) cartridges boosts efficiency in pharmaceutical filling processes by up to 67% and significantly reduces CO2 emissions by close to 25% in the supply chain for 1.5 ml RTU cartridges......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.12.2024
1SXP
LISTED
XETR
SCHOTT Pharma präsentiert innovatives Nestdesign für vorsterilisierte Karpulen
News Preview
Effizient und nachhaltig: SCHOTT Pharma präsentiert innovatives Nestdesign für vorsterilisierte Karpulen
Neues rautenförmiges Nest für vorsterilisierte, ready-to-use (RTU)-Karpulen steigert die Effizienz von pharmazeutischen Abfüllprozessen um bis zu 67% und reduziert die CO2-Emissionen in der Lieferkette um beinahe 25% für 1,5 ml Karpulen.
Je na......
Themefolio
Profiler
Peergroup
© Globe Newswire
03.12.2024
GMAB
LISTED
CPH
Capital Increase in Genmab as a Result of Employee Warrant Exercise
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.12.2024
MURA
LISTED
NASDAQ
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
WALTHAM, Mass and DUBLIN, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on December 2, the Company granted to four newl...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.12.2024
CHEMM
LISTED
CPH
Upgrade of revenue and operating profit guidance
News Preview
ANNOUNCEMENT NO. 285...
Themefolio
Profiler
Peergroup
© EQS Newswire
03.12.2024
EUZ
LISTED
XETR
Changes in the Executive Board and Supervisory Board
News Preview
Berlin, 3 December 2024. The Supervisory Board of Eckert & Ziegler SE has appointed Dr. Gunnar Mann (57) as a new member of the Executive Board, effective 1 January 2025. He will assume operational responsibility for the Medical segment.
Dr. Mann who holds a doctorate in physics, joined Eckert & Ziegler in 1998 and initially started as head......
Themefolio
Profiler
Peergroup
© EQS Newswire
03.12.2024
EUZ
LISTED
XETR
Wechsel in Vorstand und Aufsichtsrat
News Preview
Berlin, 3. Dezember 2024. Der Aufsichtsrat der Eckert & Ziegler SE hat Dr. Gunnar Mann (57) mit Wirkung zum 1.1.2025 als neues Vorstandsmitglied bestellt. Er wird die operative Verantwortung für das Segment Medical übernehmen.
Der promovierte Physiker kam 1998 zu Eckert & Ziegler und startete zunächst als Entwicklungsleiter. Danach war er a......
Themefolio
Profiler
Peergroup
© BusinessWire
03.12.2024
DFTX
LISTED
NASDAQ
MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Javier A. Muniz, M.D., as Vice President of Research and Development (R&D) Strategy. In his new role, Dr. Muniz will drive...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.12.2024
GMAB
LISTED
CPH
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© PR Newswire
03.12.2024
VITR
LISTED
STO
Patrik Tolf steps down as CFO of the Vitrolife Group - Helena Wennerström appointed acting CFO
News Preview
GOTHENBURG, Sweden, Dec. 3, 2024 /PRNewswire/ -- Vitrolife AB (publ) announces today that Patrik Tolf will be stepping down as Chief Financial Officer due to personal reasons. Helena Wennerström will assume the role of acting CFO. Helena has extensive experience in finance and business management, including having served as CFO at ViaCon Group AB...
Themefolio
Profiler
Peergroup
© PR Newswire
03.12.2024
HNSA
LISTED
STO
Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome
News Preview
The trial will be conducted in patients with pre-existing anti-AAV antibodies which limit use of gene therapy treatment.
LUND, Sweden and EVRY, France, Dec. 3, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) and Genethon, a pioneer and a leader in gene therapy research and development for rare genetic diseases, today announ...
Themefolio
Profiler
Peergroup
© PR Newswire
03.12.2024
HNSA
LISTED
STO
Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome
News Preview
The trial will be conducted in patients with pre-existing anti-AAV antibodies which limit use of gene therapy treatment.
LUND, Sweden and EVRY, France, Dec. 3, 2024 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA) and Genethon, a pioneer and a leader in gene therapy research and development for rare genetic diseases, today announ...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.12.2024
IMCR
LISTED
NASDAQ
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
News Preview
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.12.2024
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Strengthens Leadership and Executive Committee
News Preview
OSE Immunotherapeutics Strengthens Leadership and Executive Committee...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
